Cargando…
Antipsychotic Prescribing to Patients Diagnosed with Dementia Without a Diagnosis of Psychosis in the Context of National Guidance and Drug Safety Warnings: Longitudinal Study in UK General Practice
INTRODUCTION: Policy interventions to address inappropriate prescribing of antipsychotic drugs to older people diagnosed with dementia are commonplace. In the UK, warnings were issued by the Medicines Healthcare products Regulatory Agency in 2004, 2009 and 2012 and the National Institute for Health...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519656/ https://www.ncbi.nlm.nih.gov/pubmed/28439716 http://dx.doi.org/10.1007/s40264-017-0538-x |
_version_ | 1783251664253222912 |
---|---|
author | Stocks, S. Jill Kontopantelis, Evangelos Webb, Roger T. Avery, Anthony J. Burns, Alistair Ashcroft, Darren M. |
author_facet | Stocks, S. Jill Kontopantelis, Evangelos Webb, Roger T. Avery, Anthony J. Burns, Alistair Ashcroft, Darren M. |
author_sort | Stocks, S. Jill |
collection | PubMed |
description | INTRODUCTION: Policy interventions to address inappropriate prescribing of antipsychotic drugs to older people diagnosed with dementia are commonplace. In the UK, warnings were issued by the Medicines Healthcare products Regulatory Agency in 2004, 2009 and 2012 and the National Institute for Health and Care Excellence guidance was published in 2006. It is important to evaluate the impact of such interventions. METHODS: We analysed routinely collected primary-care data from 111,346 patients attending one of 689 general practices contributing to the Clinical Practice Research Datalink to describe the temporal changes in the prescribing of antipsychotic drugs to patients aged 65 years or over diagnosed with dementia without a concomitant psychosis diagnosis from 2001 to 2014 using an interrupted time series and a before-and-after design. Logistic regression methods were used to quantify the impact of patient and practice level variables on prescribing prevalence. RESULTS: Prescribing of first-generation antipsychotic drugs reduced from 8.9% in 2001 to 1.4% in 2014 (prevalence ratio 2014/2001 adjusted for age, sex and clustering within practices (0.14, 95% confidence interval 0.12–0.16), whereas there was little change for second-generation antipsychotic drugs (1.01, confidence interval 0.94–1.17). Between 2004 and 2012, several policy interventions coincided with a pattern of ups and downs, whereas the 2006 National Institute for Health and Care Excellence guidance was followed by a gradual longer term reduction. Since 2013, the decreasing trend in second-generation antipsychotic drug prescribing has plateaued largely driven by the increasing prescribing of risperidone. CONCLUSIONS: Increased surveillance and evaluation of drug safety warnings and guidance are needed to improve the impact of future interventions. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40264-017-0538-x) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5519656 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-55196562017-08-01 Antipsychotic Prescribing to Patients Diagnosed with Dementia Without a Diagnosis of Psychosis in the Context of National Guidance and Drug Safety Warnings: Longitudinal Study in UK General Practice Stocks, S. Jill Kontopantelis, Evangelos Webb, Roger T. Avery, Anthony J. Burns, Alistair Ashcroft, Darren M. Drug Saf Original Research Article INTRODUCTION: Policy interventions to address inappropriate prescribing of antipsychotic drugs to older people diagnosed with dementia are commonplace. In the UK, warnings were issued by the Medicines Healthcare products Regulatory Agency in 2004, 2009 and 2012 and the National Institute for Health and Care Excellence guidance was published in 2006. It is important to evaluate the impact of such interventions. METHODS: We analysed routinely collected primary-care data from 111,346 patients attending one of 689 general practices contributing to the Clinical Practice Research Datalink to describe the temporal changes in the prescribing of antipsychotic drugs to patients aged 65 years or over diagnosed with dementia without a concomitant psychosis diagnosis from 2001 to 2014 using an interrupted time series and a before-and-after design. Logistic regression methods were used to quantify the impact of patient and practice level variables on prescribing prevalence. RESULTS: Prescribing of first-generation antipsychotic drugs reduced from 8.9% in 2001 to 1.4% in 2014 (prevalence ratio 2014/2001 adjusted for age, sex and clustering within practices (0.14, 95% confidence interval 0.12–0.16), whereas there was little change for second-generation antipsychotic drugs (1.01, confidence interval 0.94–1.17). Between 2004 and 2012, several policy interventions coincided with a pattern of ups and downs, whereas the 2006 National Institute for Health and Care Excellence guidance was followed by a gradual longer term reduction. Since 2013, the decreasing trend in second-generation antipsychotic drug prescribing has plateaued largely driven by the increasing prescribing of risperidone. CONCLUSIONS: Increased surveillance and evaluation of drug safety warnings and guidance are needed to improve the impact of future interventions. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40264-017-0538-x) contains supplementary material, which is available to authorized users. Springer International Publishing 2017-04-24 2017 /pmc/articles/PMC5519656/ /pubmed/28439716 http://dx.doi.org/10.1007/s40264-017-0538-x Text en © The Author(s) 2017, corrected publication 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Article Stocks, S. Jill Kontopantelis, Evangelos Webb, Roger T. Avery, Anthony J. Burns, Alistair Ashcroft, Darren M. Antipsychotic Prescribing to Patients Diagnosed with Dementia Without a Diagnosis of Psychosis in the Context of National Guidance and Drug Safety Warnings: Longitudinal Study in UK General Practice |
title | Antipsychotic Prescribing to Patients Diagnosed with Dementia Without a Diagnosis of Psychosis in the Context of National Guidance and Drug Safety Warnings: Longitudinal Study in UK General Practice |
title_full | Antipsychotic Prescribing to Patients Diagnosed with Dementia Without a Diagnosis of Psychosis in the Context of National Guidance and Drug Safety Warnings: Longitudinal Study in UK General Practice |
title_fullStr | Antipsychotic Prescribing to Patients Diagnosed with Dementia Without a Diagnosis of Psychosis in the Context of National Guidance and Drug Safety Warnings: Longitudinal Study in UK General Practice |
title_full_unstemmed | Antipsychotic Prescribing to Patients Diagnosed with Dementia Without a Diagnosis of Psychosis in the Context of National Guidance and Drug Safety Warnings: Longitudinal Study in UK General Practice |
title_short | Antipsychotic Prescribing to Patients Diagnosed with Dementia Without a Diagnosis of Psychosis in the Context of National Guidance and Drug Safety Warnings: Longitudinal Study in UK General Practice |
title_sort | antipsychotic prescribing to patients diagnosed with dementia without a diagnosis of psychosis in the context of national guidance and drug safety warnings: longitudinal study in uk general practice |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519656/ https://www.ncbi.nlm.nih.gov/pubmed/28439716 http://dx.doi.org/10.1007/s40264-017-0538-x |
work_keys_str_mv | AT stockssjill antipsychoticprescribingtopatientsdiagnosedwithdementiawithoutadiagnosisofpsychosisinthecontextofnationalguidanceanddrugsafetywarningslongitudinalstudyinukgeneralpractice AT kontopantelisevangelos antipsychoticprescribingtopatientsdiagnosedwithdementiawithoutadiagnosisofpsychosisinthecontextofnationalguidanceanddrugsafetywarningslongitudinalstudyinukgeneralpractice AT webbrogert antipsychoticprescribingtopatientsdiagnosedwithdementiawithoutadiagnosisofpsychosisinthecontextofnationalguidanceanddrugsafetywarningslongitudinalstudyinukgeneralpractice AT averyanthonyj antipsychoticprescribingtopatientsdiagnosedwithdementiawithoutadiagnosisofpsychosisinthecontextofnationalguidanceanddrugsafetywarningslongitudinalstudyinukgeneralpractice AT burnsalistair antipsychoticprescribingtopatientsdiagnosedwithdementiawithoutadiagnosisofpsychosisinthecontextofnationalguidanceanddrugsafetywarningslongitudinalstudyinukgeneralpractice AT ashcroftdarrenm antipsychoticprescribingtopatientsdiagnosedwithdementiawithoutadiagnosisofpsychosisinthecontextofnationalguidanceanddrugsafetywarningslongitudinalstudyinukgeneralpractice |